Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cingal 16-02 for Knee Osteoarthritis
NCT03191903Phase 3Completed
- Sponsor
- Anika Therapeutics
- Start
- May 2017
- Primary completion
- Apr 2018
- Modality
- Injectable Hydrogels, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of triamcinolone hexacetonide + hyaluronic acid in osteoarthritis (OA) (3 arms), sponsored by Anika Therapeutics. Primary endpoint: Change From Baseline in WOMAC Pain Score at 26 weeks. Started May 2017; status: completed.
02
Drugs
triamcinolone hexacetonide + hyaluronic acid
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03191903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03191903.